vertex suzetrigine - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

Scientific American · 3d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Time on MSN · 5h

FDA Approves the First Non-Opioid Pain Medicine in 20 Years

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.

BioSpace · 3d

FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

21h

Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

AFP3d

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

4don MSN

Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

18h

Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Zacks.com on MSN13h

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results